Based on these finding, PDE9A inhibitors have been advanced into initial clinical studies to assess the potential to improve cognitive function in patients with Alzheimer’s disease and schizophrenia (Schwam et al., 2014; Wunderlich et al., 2016; Boland et al., 2017). The gene discussed is PDE9A; the disease is Alzheimer disease.